Legal & General Group PLC Erasca, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Erasca, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 122,251 shares of ERAS stock, worth $326,410. This represents 0.0% of its overall portfolio holdings.

Number of Shares

122,251

Previous 122,251 -0.0%

Holding current value

$326,410

Previous $333,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.17 - $3.28 $244,131 - $369,009	112,503 Added 1154.11%	122,251 $333,000
Q2 2024 Aug 14, 2024	BUY	$1.79 - $2.63 $5,824 - $8,558	3,254 Added 50.11%	9,748 $23,000
Q1 2024 May 14, 2024	SELL	$1.67 - $2.55 $148,072 - $226,098	-88,666 Reduced 93.18%	6,494 $13,000
Q3 2023 Nov 14, 2023	SELL	$1.97 - $2.91 $2,921 - $4,315	-1,483 Reduced 1.53%	95,160 $187,000
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $183,176 - $235,207	71,275 Added 280.96%	96,643 $266,000
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $7,929 - $12,849	2,894 Added 12.88%	25,368 $76,000
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $34,045 - $75,004	8,752 Added 63.78%	22,474 $96,000
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $3,654 - $6,707	628 Added 4.8%	13,722 $107,000
Q2 2022 Aug 22, 2022	BUY	$4.58 - $8.72 $2,853 - $5,432	623 Added 5.0%	13,094 $72,000
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $36,025 - $64,845	4,189 Added 50.58%	12,471 $108,000
Q4 2021 Feb 14, 2022	BUY	$12.51 - $22.75 $79,513 - $144,599	6,356 Added 330.01%	8,282 $129,000
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $33,570 - $46,878	1,926 New	1,926 $41,000

Others Institutions Holding ERAS

# of Institutions

141

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $326M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Erasca, Inc. Transaction History